AstraZeneca’s trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?

In this article AZN-GB ALNY XBI Follow your favorite stocksCREATE FREE ACCOUNT AstraZeneca‘s failed late-stage trial for Wainua was never expected to have a major

Tag: vulnerable

AstraZeneca’s trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?

The Newest Way to Go Analog

Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC

What is the impact of climate change and adverse weather on summers in the UK?

AstraZeneca’s trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?

This Kind of Obsessive Attraction Isn’t Love. But It Has a Name.

Two Telehealth Executives Sentenced for Scheme to Distribute Adderall

A Proposed Rule Would Politicize Medical Research. Scientists Are Not Happy.